Abstract
Nucleotide metabolism has been targeted for many years and in various clinical settings, including cancer. The increased knowledge of certain enzymes involved in this metabolism and associated cellular processes accumulated over the last few years, gives important information related to the druggability of certain proteins and the use of inhibitors for others. Here, we review recent data on such enzymes with a major interest in drug development, i.e. SAMHD1 and the proteins of the NUDIX family. These include information on their roles in cancer progression, correlations with clinical outcomes in cancer patients, and the development and study of enzymatic inhibitors.
Keywords: NUDIX, MTH1, SAMHD1, cancer, treatment, inhibitors.
Current Medicinal Chemistry
Title:Targeting the Nucleotide Metabolism Proteins of the NUDIX Family and SAMHD1 in Cancer
Volume: 28 Issue: 21
Author(s): Prescillia Forey, Emeline Cros-Perrial, Charles Dumontet and Lars Petter Jordheim*
Affiliation:
- Univ Lyon, Universite Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Leon Berard, Centre de Recherche en Cancerologie de Lyon, Lyon, 69008,France
Keywords: NUDIX, MTH1, SAMHD1, cancer, treatment, inhibitors.
Abstract: Nucleotide metabolism has been targeted for many years and in various clinical settings, including cancer. The increased knowledge of certain enzymes involved in this metabolism and associated cellular processes accumulated over the last few years, gives important information related to the druggability of certain proteins and the use of inhibitors for others. Here, we review recent data on such enzymes with a major interest in drug development, i.e. SAMHD1 and the proteins of the NUDIX family. These include information on their roles in cancer progression, correlations with clinical outcomes in cancer patients, and the development and study of enzymatic inhibitors.
Export Options
About this article
Cite this article as:
Forey Prescillia , Cros-Perrial Emeline , Dumontet Charles and Jordheim Petter Lars *, Targeting the Nucleotide Metabolism Proteins of the NUDIX Family and SAMHD1 in Cancer, Current Medicinal Chemistry 2021; 28 (21) . https://dx.doi.org/10.2174/0929867328666201125120422
DOI https://dx.doi.org/10.2174/0929867328666201125120422 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Targeting of G-Protein Coupled Receptor-Mediated Epidermal Growth Factor Receptor Transactivation in Human Glioma Brain Tumors
Mini-Reviews in Medicinal Chemistry The Role of ABC Transporters in Protecting Cells from Bilirubin Toxicity
Current Pharmaceutical Design Biomedical Applications of Poly(Lactic Acid)
Recent Patents on Regenerative Medicine Radiological Assessment of Giant Cell Tumour of Bone in the Sacrum: From Diagnosis to Treatment Response Evaluation
Current Medical Imaging Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals
Current Topics in Medicinal Chemistry Recent Developments in the Synthesis of Antitumor-active Glycyrrhetinic Acid Derivatives
Mini-Reviews in Organic Chemistry Therapeutic Strategies in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)
Central Nervous System Agents in Medicinal Chemistry Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Recent Patents on Anti-Cancer Drug Discovery Update on Evidence that Support a Role of Solar Ultraviolet-B Irradiance in Reducing Cancer Risk
Anti-Cancer Agents in Medicinal Chemistry Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology Nutritional Antioxidants and Adaptive Cell Responses: An Update
Current Molecular Medicine 18F-Labeled Proteins
Current Pharmaceutical Biotechnology Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy
Clinical Cancer Drugs Therapeutic Targeting of Cancers with Loss of PTEN Function
Current Drug Targets Flavonoids in Atherosclerosis: An Overview of Their Mechanisms of Action
Current Medicinal Chemistry Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry Recent Updates in Imperative Natural Compounds for Healthy Brain and Nerve Function: A Systematic Review of Implications for Multiple Sclerosis
Current Drug Targets Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression
Anti-Cancer Agents in Medicinal Chemistry